Mar 30, 2020 5:05pm EDT IMV Inc. Announces Fourth Quarter and Full Year 2019 Financial and Operational Results
Mar 30, 2020 7:05am EDT IMV Inc. Provides Updates on the Development of DPX-COVID-19 Vaccine, Its Ongoing Business and Clinical Operations
Mar 25, 2020 7:05am EDT IMV to Announce Fourth Quarter and Full Year 2019 Financial and Operational Results and Host Investor Conference Call and Webcast on March 31, 2020
Mar 18, 2020 7:05am EDT IMV Inc. Launches Plans to Advance Clinical Development of a Vaccine Candidate Against COVID-19
Feb 25, 2020 3:05am EST IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer
Feb 20, 2020 7:05am EST IMV to Host Conference Call & Webcast to Report Updated Results from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer
Feb 04, 2020 7:05am EST Clinical Translational Data Supporting DPX-Survivac Mechanism of Action to be Presented at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
